BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32591138)

  • 1. [Metastatic squamous cell carcinomas of the anal canal: Current management and prospects].
    Saint A; Evesque L; François É
    Bull Cancer; 2020; 107(7-8):792-799. PubMed ID: 32591138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
    Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
    Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
    Khawandanah M; Baxley A; Pant S
    J Oncol Pharm Pract; 2015 Jun; 21(3):232-7. PubMed ID: 24627343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
    Kim S; Buecher B; André T; Jary M; Bidard FC; Ghiringhelli F; François É; Taieb J; Smith D; de la Fouchardière C; Desramé J; Samalin E; Parzy A; Baba-Hamed N; Bouché O; Tougeron D; Dahan L; El Hajbi F; Jacquin M; Rebucci-Peixoto M; Spehner L; Vendrely V; Vernerey D; Borg C
    BMC Cancer; 2020 Apr; 20(1):352. PubMed ID: 32334548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.
    Eng C; Chang GJ; You YN; Das P; Rodriguez-Bigas M; Xing Y; Vauthey JN; Rogers JE; Ohinata A; Pathak P; Sethi S; Phillips JK; Crane CH; Wolff RA
    Oncotarget; 2014 Nov; 5(22):11133-42. PubMed ID: 25373735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Therapies for Advanced Squamous Cell Anal Cancer.
    Sclafani F; Rao S
    Curr Oncol Rep; 2018 May; 20(7):53. PubMed ID: 29728940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
    Stouvenot M; Meurisse A; Saint A; Buecher B; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Smith D; Ghiringhelli F; Parzy A; de la Fouchardiere C; Almotlak H; Vienot A; Jacquin M; Taieb J; Nguyen T; Vernerey D; Borg C; Kim S
    Eur J Cancer; 2022 Feb; 162():138-147. PubMed ID: 34995900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy.
    Abbas A; Nehme E; Fakih M
    Anticancer Res; 2011 Dec; 31(12):4637-40. PubMed ID: 22199342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal.
    Saint A; Evesque L; Falk AT; Cavaglione G; Montagne L; Benezery K; Francois E
    Cancer Med; 2019 Nov; 8(16):6853-6859. PubMed ID: 31524335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
    Deniaud-Alexandre E; Touboul E; Tiret E; Sezeur A; Hannoun L; Houry S; Huguet F; Pène F; Parc R; Schlienger M
    Cancer Radiother; 2006 Dec; 10(8):572-82. PubMed ID: 17110148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report of long term survivor of metastatic cloacogenic carcinoma of the anal canal with chemotherapy.
    Fayaz S; Vasishta S; Motawy M
    Gulf J Oncolog; 2007 Jul; (2):65-8. PubMed ID: 20084726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New approaches in palliative systemic therapy of anal squamous cell carcinoma.
    Lohynská R; Pechačová Z
    Klin Onkol; 2022; 35(3):190-194. PubMed ID: 35760571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Definitive chemoradiotherapy for anal canal cancer: single-center experience.
    Tachibana I; Nishimura Y; Inada M; Fukuda K; Ishikawa K; Nishikawa T; Yokokawa M; Nakamatsu K; Kanamori S; Hida JI
    Int J Clin Oncol; 2018 Dec; 23(6):1121-1126. PubMed ID: 29992389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma.
    Kim S; Jary M; Mansi L; Benzidane B; Cazorla A; Demarchi M; Nguyen T; Kaliski A; Delabrousse E; Bonnetain F; Letondal P; Bosset JF; Valmary-Degano S; Borg C
    Ann Oncol; 2013 Dec; 24(12):3045-50. PubMed ID: 24114858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor inhibition in metastatic anal cancer.
    Rogers JE; Ohinata A; Silva NN; Mehdizadeh A; Eng C
    Anticancer Drugs; 2016 Sep; 27(8):804-8. PubMed ID: 27272412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
    Kim S; Jary M; André T; Vendrely V; Buecher B; François E; Bidard FC; Dumont S; Samalin E; Peiffert D; Pernot S; Baba-Hamed N; El Hajbi F; Bouché O; Desrame J; Parzy A; Zoubir M; Louvet C; Bachet JB; Nguyen T; Abdelghani MB; Smith D; De La Fouchardière C; Aparicio T; Bennouna J; Gornet JM; Jacquin M; Bonnetain F; Borg C
    BMC Cancer; 2017 Aug; 17(1):574. PubMed ID: 28841909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Squamous cell anal carcinoma. What's next ?].
    Kim S; Spehner L; Cabel L; Bidard FC; Borg C
    Bull Cancer; 2021 Jan; 108(1):80-89. PubMed ID: 33423780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboplatin and paclitaxel treatment is effective in advanced anal cancer.
    Kim R; Byer J; Fulp WJ; Mahipal A; Dinwoodie W; Shibata D
    Oncology; 2014; 87(2):125-32. PubMed ID: 25012155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer.
    Mondaca S; Chatila WK; Bates D; Hechtman JF; Cercek A; Segal NH; Stadler ZK; Varghese AM; Kundra R; Capanu M; Shia J; Schultz N; Saltz L; Yaeger R
    Clin Colorectal Cancer; 2019 Mar; 18(1):e39-e52. PubMed ID: 30316684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Squamous cell carcinoma of the anal canal.
    Mitchell SE; Mendenhall WM; Zlotecki RA; Carroll RR
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1007-13. PubMed ID: 11240241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.